JP2021513552A5 - - Google Patents
Info
- Publication number
- JP2021513552A5 JP2021513552A5 JP2020543742A JP2020543742A JP2021513552A5 JP 2021513552 A5 JP2021513552 A5 JP 2021513552A5 JP 2020543742 A JP2020543742 A JP 2020543742A JP 2020543742 A JP2020543742 A JP 2020543742A JP 2021513552 A5 JP2021513552 A5 JP 2021513552A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- drug
- ibutamorene
- ghs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023221157A JP2024028337A (ja) | 2018-02-14 | 2023-12-27 | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 |
| JP2025129927A JP2025179056A (ja) | 2018-02-14 | 2025-08-04 | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630361P | 2018-02-14 | 2018-02-14 | |
| US62/630,361 | 2018-02-14 | ||
| PCT/US2019/017964 WO2019161025A1 (en) | 2018-02-14 | 2019-02-14 | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023221157A Division JP2024028337A (ja) | 2018-02-14 | 2023-12-27 | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513552A JP2021513552A (ja) | 2021-05-27 |
| JP2021513552A5 true JP2021513552A5 (enExample) | 2022-02-21 |
Family
ID=67620042
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543742A Withdrawn JP2021513552A (ja) | 2018-02-14 | 2019-02-14 | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 |
| JP2023221157A Pending JP2024028337A (ja) | 2018-02-14 | 2023-12-27 | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 |
| JP2025129927A Pending JP2025179056A (ja) | 2018-02-14 | 2025-08-04 | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023221157A Pending JP2024028337A (ja) | 2018-02-14 | 2023-12-27 | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 |
| JP2025129927A Pending JP2025179056A (ja) | 2018-02-14 | 2025-08-04 | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20210059993A1 (enExample) |
| EP (3) | EP4467158A3 (enExample) |
| JP (3) | JP2021513552A (enExample) |
| KR (2) | KR20240015742A (enExample) |
| CN (2) | CN118453597A (enExample) |
| AU (2) | AU2019222736B2 (enExample) |
| BR (1) | BR112020016613A2 (enExample) |
| CA (1) | CA3088177A1 (enExample) |
| EA (1) | EA202091464A1 (enExample) |
| WO (1) | WO2019161025A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020205498A1 (en) * | 2019-03-29 | 2020-10-08 | The General Hospital Corporation | Ghrh or analogues thereof for use in treatment of hepatic disease |
| CA3192690A1 (en) * | 2020-09-18 | 2022-03-24 | Seung Yong Seong | Pharmaceutical composition for treating nonalcoholic steatohepatitis and liver fibrosis |
| KR20220132312A (ko) | 2021-03-23 | 2022-09-30 | 한국과학기술원 | 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법 |
| GEAP202516774A (en) | 2022-11-03 | 2025-06-25 | Lumos Pharma Inc | Compactable oral formulations of ibutamoren |
| WO2025193784A1 (en) * | 2024-03-12 | 2025-09-18 | Lumos Pharma, Inc. | Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment |
| WO2025217521A1 (en) * | 2024-04-12 | 2025-10-16 | Jnana Therapeutics Inc. | Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist |
| CN119405782A (zh) * | 2025-01-06 | 2025-02-11 | 山东大学 | 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US20070123470A1 (en) * | 2003-10-24 | 2007-05-31 | Wladimir Hogenhuis | Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue |
| JP2007532495A (ja) * | 2004-04-07 | 2007-11-15 | ガストロテック・ファルマ・アクティーゼルスカブ | グレリン欠乏を治療するための分泌促進薬の使用 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
| AU2015314830B2 (en) * | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| RU2018113437A (ru) * | 2015-09-16 | 2019-10-17 | Тобира Терапьютикс, Инк. | Комбинированная терапия с использованием ценикривирока для лечения фиброза |
| WO2019008554A1 (en) * | 2017-07-06 | 2019-01-10 | Conte Anthony | METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE |
-
2019
- 2019-02-14 EP EP24205490.6A patent/EP4467158A3/en not_active Withdrawn
- 2019-02-14 CN CN202410528969.XA patent/CN118453597A/zh active Pending
- 2019-02-14 EP EP19755124.5A patent/EP3781158A4/en not_active Ceased
- 2019-02-14 BR BR112020016613-8A patent/BR112020016613A2/pt not_active Application Discontinuation
- 2019-02-14 KR KR1020247002905A patent/KR20240015742A/ko not_active Ceased
- 2019-02-14 EP EP25195764.3A patent/EP4623929A3/en active Pending
- 2019-02-14 US US16/961,564 patent/US20210059993A1/en not_active Abandoned
- 2019-02-14 JP JP2020543742A patent/JP2021513552A/ja not_active Withdrawn
- 2019-02-14 KR KR1020207023368A patent/KR20200121308A/ko not_active Ceased
- 2019-02-14 EA EA202091464A patent/EA202091464A1/ru unknown
- 2019-02-14 CA CA3088177A patent/CA3088177A1/en active Pending
- 2019-02-14 AU AU2019222736A patent/AU2019222736B2/en active Active
- 2019-02-14 CN CN201980013533.4A patent/CN111727041A/zh active Pending
- 2019-02-14 WO PCT/US2019/017964 patent/WO2019161025A1/en not_active Ceased
-
2023
- 2023-08-09 US US18/231,977 patent/US20230381158A1/en not_active Abandoned
- 2023-12-27 JP JP2023221157A patent/JP2024028337A/ja active Pending
-
2024
- 2024-08-07 AU AU2024205599A patent/AU2024205599A1/en not_active Abandoned
-
2025
- 2025-05-27 US US19/219,112 patent/US20250281470A1/en active Pending
- 2025-08-04 JP JP2025129927A patent/JP2025179056A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11938124B2 (en) | Combination therapy for treatment of cancer | |
| CN101374523B (zh) | 用于治疗糖尿病的二肽基肽酶抑制剂 | |
| JP5827706B2 (ja) | 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法 | |
| RU2384333C2 (ru) | Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин | |
| NO342004B1 (no) | 2-[6-(3-amino-piperidin-1-yl)-3-metyl-2,4-diokso-3,4-dihydro-2H-pyrimidin-1-ylmetyl]-4-fluor-benzonitril for anvendelse som et medikament for behandling av diabetes, cancer, en autoimmun sykdom eller HIV infeksjon | |
| US20050014732A1 (en) | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | |
| AU2022308121B2 (en) | Combination therapy for treatment of liver diseases | |
| TWI842924B (zh) | Gpr119致效劑及dpp-4抑制劑的藥物組合及藥物套組 | |
| TW200932249A (en) | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors | |
| RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита | |
| JP2022500483A5 (enExample) | ||
| JP2018519340A5 (enExample) | ||
| TW201208702A (en) | Combination therapy for treating cancer comprising an IGF-1R inhibitor and an Akt inhibitor | |
| KR20100015524A (ko) | 디펩티딜 펩티다아제 억제제의 주1회 투여 | |
| CN113573700A (zh) | 化合物的制剂及其用途 | |
| JP2021522247A5 (enExample) | ||
| EP4467158A3 (en) | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis | |
| JP2024016209A5 (enExample) | ||
| Gaudilliere et al. | To market, to market—2000 | |
| JP2023507364A (ja) | インテグリン阻害剤を使用する肝疾患の治療の組み合わせ | |
| CN118946371A (zh) | 靶向psma的放射性药物和检查点抑制剂的组合疗法 | |
| US20240293385A1 (en) | Combination therapy for treatment of liver diseases | |
| JP2005503391A5 (enExample) | ||
| RU2818562C2 (ru) | Комбинированная терапия агонистами gpr119 и ингибиторами dpp-4 | |
| US12559553B2 (en) | IL-31 modulators for treating FXR-induced pruritus |